US Bancorp
SANA icon

US Bancorp’s Sana Biotechnology SANA Stock Holding History

US Bancorp’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
694
+109
+19% +$429 ﹤0.01% 3806
2025
Q4 		$2.38K Hold
585
– – ﹤0.01% 3729
2025
Q3 		$2.08K Sell
585
-85
-13% -$307 ﹤0.01% 3753
2025
Q2 		$1.83K Buy
670
+64
+11% +$132 ﹤0.01% 3877
2025
Q1 		$1.02K Buy
606
+68
+13% +$190 ﹤0.01% 3986
2024
Q4 		$877 Sell
538
-112
-17% -$334 ﹤0.01% 3975
2024
Q3 		$2.7K Sell
650
-205
-24% -$1.08K ﹤0.01% 3715
2024
Q2 		$4.67K Buy
855
+523
+158% +$4.17K ﹤0.01% 3538
2024
Q1 		$3.32K Hold
332
– – ﹤0.01% 3621
2023
Q4 		$1.35K Buy
+332
New +$1.22K ﹤0.01% 3764
2023
Q2 		– Sell
-4,202
Closed -$13.7K – 4117
2023
Q1 		$13.7K Buy
+4,202
New +$16.8K ﹤0.01% 3165
2021
Q3 		– Sell
-21
Closed – – 4171
2021
Q2 		$0 Buy
21
+8
+62% +$181 ﹤0.01% 4063
2021
Q1 		$0 Buy
+13
New +$423 ﹤0.01% 3954

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

US Bancorp's SANA Position: Q1 2026 in Review

US Bancorp increased its Sana Biotechnology (SANA) stake by 19% in Q1 2026, buying an estimated $429 and bringing the position to 694 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3806.

US Bancorp first reported a position in SANA in Q1 2021 and has held it in 13 quarters since. The position peaked at $13.7K in Q1 2023. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • US Bancorp held 694 shares of Sana Biotechnology worth $2K as of Q1 2026.
  • US Bancorp bought 109 Sana Biotechnology shares in Q1 2026, an estimated $429.
  • Sana Biotechnology made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3806 holding.
  • US Bancorp first reported a position in Sana Biotechnology in Q1 2021 and has held it in 13 quarters since.
  • US Bancorp's Sana Biotechnology position peaked at $13.7K in Q1 2023.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.